全文获取类型
收费全文 | 57609篇 |
免费 | 4564篇 |
国内免费 | 2160篇 |
专业分类
耳鼻咽喉 | 235篇 |
儿科学 | 1000篇 |
妇产科学 | 608篇 |
基础医学 | 7396篇 |
口腔科学 | 667篇 |
临床医学 | 5125篇 |
内科学 | 14575篇 |
皮肤病学 | 736篇 |
神经病学 | 3463篇 |
特种医学 | 1510篇 |
外国民族医学 | 4篇 |
外科学 | 4310篇 |
综合类 | 7407篇 |
现状与发展 | 5篇 |
一般理论 | 2篇 |
预防医学 | 4587篇 |
眼科学 | 993篇 |
药学 | 7221篇 |
104篇 | |
中国医学 | 1891篇 |
肿瘤学 | 2494篇 |
出版年
2023年 | 738篇 |
2022年 | 1497篇 |
2021年 | 1911篇 |
2020年 | 1906篇 |
2019年 | 2244篇 |
2018年 | 2209篇 |
2017年 | 2084篇 |
2016年 | 2137篇 |
2015年 | 2190篇 |
2014年 | 3815篇 |
2013年 | 4191篇 |
2012年 | 3285篇 |
2011年 | 3519篇 |
2010年 | 2612篇 |
2009年 | 2479篇 |
2008年 | 2445篇 |
2007年 | 2676篇 |
2006年 | 2309篇 |
2005年 | 2042篇 |
2004年 | 1750篇 |
2003年 | 1603篇 |
2002年 | 1355篇 |
2001年 | 1213篇 |
2000年 | 1029篇 |
1999年 | 921篇 |
1998年 | 808篇 |
1997年 | 830篇 |
1996年 | 649篇 |
1995年 | 640篇 |
1994年 | 565篇 |
1993年 | 440篇 |
1992年 | 374篇 |
1991年 | 298篇 |
1990年 | 239篇 |
1989年 | 210篇 |
1988年 | 176篇 |
1987年 | 153篇 |
1985年 | 494篇 |
1984年 | 582篇 |
1983年 | 462篇 |
1982年 | 438篇 |
1981年 | 416篇 |
1980年 | 369篇 |
1979年 | 330篇 |
1978年 | 284篇 |
1977年 | 209篇 |
1976年 | 250篇 |
1975年 | 252篇 |
1974年 | 198篇 |
1973年 | 178篇 |
排序方式: 共有10000条查询结果,搜索用时 8 毫秒
1.
2.
内生菌由细菌、真菌、古菌和原生生物组成,它们生活在植物的活体组织中,具有丰富的次级代谢产物多样性。人参内生菌在人参的生长发育、次级代谢产物的生成和环境适应等方面均有重要的促进作用,对人参的产量和品质有较大影响。随着人们在微生物领域研究的深入,高通量测序技术已经成为研究植物内生菌的重要方法。文章主要从人参内生菌分离与鉴定研究方法、人参内生菌的多样性、人参内生菌及其次级代谢产物的活性、人参内生菌对宿主的影响等4个方面对人参内生菌近年来的研究进展进行讨论,并对其发展方向提出展望,以期为药用植物内生菌研究和品质改良提供新思路、新方法。 相似文献
3.
4.
5.
目的:观察理筋通督手法治疗颈性眩晕的临床疗效。方法:将120例颈性眩晕患者随机分成3组,理筋通督组、传统手法组及安慰剂组。理筋通督组采用理筋通督手法;传统手法组采用传统手法;安慰剂组口服维生素C。结果:理筋通督手法可显著减缓患者基底动脉舒张期最低血流速度(P0.05)。理筋通督组有效率为93.67%,传统手法组有效率为67.5%,安慰剂组有效率为17.5%,3组比较差异有统计学意义(P0.05),理筋通督组明显优于其他两组。结论:理筋通督手法治疗颈性眩晕临床疗效显著。 相似文献
6.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献7.
8.
9.
《Revista espa?ola de anestesiología y reanimación》2020,67(5):245-252
Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds.In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-CoV-2). Vitamin C, a potent antioxidant, has emerged as a relevant therapy due to its potential benefits when administered intravenous. The potential effect of vitamin C in reducing inflammation in the lungs could play a key role in lung injury caused by coronavirus infection. Another potential effective therapy is ozone: it has been extensively studied and used for many years and its effectiveness has been demonstrated so far in multiples studies. Nevertheless, our goal is not to make an exhaustive review of these therapies but spread the beneficial effects themselves.Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal. 相似文献
10.
Mark Koday DDS Stephen Davis DDS Molly Melbye DDS MPH 《Journal of public health dentistry》2020,80(Z2):S114-S116
The Yakima Valley Farm Workers Clinic (YVFWC) is one of the largest community health centers in the country with clinics throughout south-central Washington and northern Oregon. Its dental program consists of 14 dental clinics providing general and specialty services to the low-income populations it serves. Modeling itself after the YVFWC medical managed care program; the Dental program recently added value-based metrics to its dental practice after Oregon offered a value-based dental reimbursement plan in 2019. This is the first-step YVFWC's dental program that has taken to prepare for value-based reimbursement and transform its dental practice in order to reduce the disease burden in its patient population. The purpose of this article is to describe the processes YVFWC undertook to prepare itself for the new reimbursement model, which included the development of metrics, a metric validation process, a clinical dashboard, and a method for improving metrics. It also outlines its medical/dental integration improvement brought about by embedding hygienists into the medical primary care teams. 相似文献